Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients
NCT ID: NCT05466721
Last Updated: 2024-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2022-06-13
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this study is to evaluate the Hydrustoma C3 medical devices (plate C3, capsule C3, night bag C3) in terms of its efficacy and safety as colostomy devices. It is also a primary objective of this study to compare the health-related quality of life in patients with colostomy when using a control and Hydrustoma C3 devices.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Investigation of New Ostomy Appliances
NCT01523756
An Investigation of Ostomy Devices
NCT01514136
Mechanical Bowel Preparation for Elective Colorectal Anastomosis
NCT02731963
Investigation of a New 1-piece Convex Ostomy Product
NCT02043782
Feasibility of a Newly Developed Ostomy Prototype
NCT07146035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hydrustoma C3
The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days.
Hydrustoma C3
The participant will use the device for 14 days.
Coloplast Alterna
The participant will use the device for 14 days.
Coloplast Alterna
The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.
Hydrustoma C3
The participant will use the device for 14 days.
Coloplast Alterna
The participant will use the device for 14 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hydrustoma C3
The participant will use the device for 14 days.
Coloplast Alterna
The participant will use the device for 14 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and Female patients;
* Adult aged ≥ 18;
* Descending and sigmoid colostomy created more than 3 months previously to the beginning of the study;
* Having formed stool and using a flat ostomy appliance;
* Able to understand the study procedures and fill questionaries;
* Able to apply and remove the ostomy device autonomously.
Exclusion Criteria
* Chronically liquid stools,
* Peristomal skin disorders,
* Known allergic reactions to components of the device,
* Receiving chemotherapy, radiation therapy or steroids in the previous month
18 Years
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hydrumedical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Palmira Peixoto
Role: PRINCIPAL_INVESTIGATOR
Hospital de Braga
Paula Costa
Role: PRINCIPAL_INVESTIGATOR
Hospital Da Senhora Da Oliveira - Guimarães
Liliana Miranda
Role: PRINCIPAL_INVESTIGATOR
Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro
Sara Costa
Role: PRINCIPAL_INVESTIGATOR
Centro Hospitalar de Entre o Douro e Vouga
Glória Gonçalves
Role: PRINCIPAL_INVESTIGATOR
Centro Hospitalar de Vila Nova de Gaia/Espinho
Carla Nunes
Role: PRINCIPAL_INVESTIGATOR
Centro Hospitalar do Tâmega e Sousa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Da Senhora Da Oliveira - Guimarães
Guimarães, Braga District, Portugal
Hospital de Braga
Braga, , Portugal
Centro Hospitalar do Tâmega e Sousa
Penafiel, , Portugal
Centro Hospitalar de Entre o Douro e Vouga
Santa Maria da Feira, , Portugal
Centro Hospitalar de Vila Nova de Gaia/Espinho
Vila Nova de Gaia, , Portugal
Centro Hospitalar de Trás-os-Montes e Alto Douro
Vila Real, , Portugal
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HydrustomaC3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.